Literature DB >> 18797473

Reprint: Good laboratory practice: preventing introduction of bias at the bench.

Malcolm R Macleod1, Marc Fisher, Victoria O'Collins, Emily S Sena, Ulrich Dirnagl, Philip M W Bath, Alastair Buchan, Alistair Buchan, H Bart van der Worp, Richard J Traystman, Kazuo Minematsu, Geoffrey A Donnan, David W Howells.   

Abstract

As a research community, we have failed to show that drugs, which show substantial efficacy in animal models of cerebral ischemia, can also improve outcome in human stroke. Accumulating evidence suggests this may be due, at least in part, to problems in the design, conduct, and reporting of animal experiments which create a systematic bias resulting in the overstatement of neuroprotective efficacy. Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.

Entities:  

Mesh:

Year:  2008        PMID: 18797473      PMCID: PMC2729492          DOI: 10.1038/jcbfm.2008.101

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  14 in total

Review 1.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development.

Authors: 
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

Review 2.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

Review 3.  Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review.

Authors:  Amy C Plint; David Moher; Andra Morrison; Kenneth Schulz; Douglas G Altman; Catherine Hill; Isabelle Gaboury
Journal:  Med J Aust       Date:  2006-09-04       Impact factor: 7.738

Review 4.  Bench to bedside: the quest for quality in experimental stroke research.

Authors:  Ulrich Dirnagl
Journal:  J Cereb Blood Flow Metab       Date:  2006-03-08       Impact factor: 6.200

5.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

Authors:  C Begg; M Cho; S Eastwood; R Horton; D Moher; I Olkin; R Pitkin; D Rennie; K F Schulz; D Simel; D F Stroup
Journal:  JAMA       Date:  1996-08-28       Impact factor: 56.272

Review 6.  Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy.

Authors:  J Grotta
Journal:  J Intern Med       Date:  1995-01       Impact factor: 8.989

7.  1,026 experimental treatments in acute stroke.

Authors:  Victoria E O'Collins; Malcolm R Macleod; Geoffrey A Donnan; Laura L Horky; Bart H van der Worp; David W Howells
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

Review 8.  Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke.

Authors:  Malcolm R Macleod; Tori O'Collins; Laura L Horky; David W Howells; Geoffrey A Donnan
Journal:  J Cereb Blood Flow Metab       Date:  2005-06       Impact factor: 6.200

9.  Quality of full and final publications reporting acute stroke trials: a systematic review.

Authors:  F J Bath; V E Owen; P M Bath
Journal:  Stroke       Date:  1998-10       Impact factor: 7.914

Review 10.  Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome.

Authors:  Chris S Weaver; Jo Leonardi-Bee; Fiona J Bath-Hextall; Philip M W Bath
Journal:  Stroke       Date:  2004-03-18       Impact factor: 7.914

View more
  25 in total

1.  Methodological quality of preclinical stroke studies is not required for publication in high-impact journals.

Authors:  Jens Minnerup; Heike Wersching; Kai Diederich; Matthias Schilling; Erich Bernd Ringelstein; Jürgen Wellmann; Wolf-Rüdiger Schäbitz
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-02       Impact factor: 6.200

2.  Fighting publication bias: introducing the Negative Results section.

Authors:  Ulrich Dirnagl; Martin Lauritzen
Journal:  J Cereb Blood Flow Metab       Date:  2010-07       Impact factor: 6.200

3.  Improving the quality of biomedical research: guidelines for reporting experiments involving animals.

Authors:  Ulrich Dirnagl; Martin Lauritzen
Journal:  J Cereb Blood Flow Metab       Date:  2011-01-05       Impact factor: 6.200

Review 4.  Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis.

Authors:  Emily S Sena; Catherine L Briscoe; David W Howells; Geoffrey A Donnan; Peter A G Sandercock; Malcolm R Macleod
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-21       Impact factor: 6.200

Review 5.  Statistics in experimental cerebrovascular research-comparison of two groups with a continuous outcome variable.

Authors:  Peter Schlattmann; Ulrich Dirnagl
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-06       Impact factor: 6.200

6.  RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION).

Authors:  Shimin Liu; Gehua Zhen; Bruno P Meloni; Kym Campbell; H Richard Winn
Journal:  J Exp Stroke Transl Med       Date:  2009-01-01

7.  Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice.

Authors:  Ulrich Dirnagl; Malcolm R Macleod
Journal:  Br J Pharmacol       Date:  2009-06-23       Impact factor: 8.739

8.  Animal models of stroke: translational potential at present and in 2050.

Authors:  Paco S Herson; Richard J Traystman
Journal:  Future Neurol       Date:  2014-09

9.  Sustained functional improvement by hepatocyte growth factor-like small molecule BB3 after focal cerebral ischemia in rats and mice.

Authors:  Rafael E Chaparro; Miwa Izutsu; Toshihiro Sasaki; Huaxin Sheng; Yi Zheng; Homa Sadeghian; Tao Qin; Daniel von Bornstadt; Fanny Herisson; Bin Duan; Jing-Song Li; Kai Jiang; Molly Pearlstein; Robert D Pearlstein; David E Smith; Itzhak D Goldberg; Cenk Ayata; David S Warner
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-25       Impact factor: 6.200

Review 10.  Update of the stroke therapy academic industry roundtable preclinical recommendations.

Authors:  Marc Fisher; Giora Feuerstein; David W Howells; Patricia D Hurn; Thomas A Kent; Sean I Savitz; Eng H Lo
Journal:  Stroke       Date:  2009-02-26       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.